Pharmacology

Sessions

  • Plenary session
  • Poster session
  • Big debate
  • Structured session
  • Workshop
  • Oral presentation session
  • Short communication session
  • Poster guided tour

Sexuality, sexual behaviour, sexual violence

Pharmacology — Aetiology
Thursday, 08 August
14:25
An online survey of perceived risks and benefits

The off-prescription use of modafinil

14:25
Wednesday, 23 October
13:20

The challenges of monitoring new drugs

13:20 to 14:50
Insights zone 2 (I2)
Ana Gallegos
15:00

New psychoactive substances

15:00 to 16:30
Networking zone 3 (N3)
Pierluigi Simonato
16:50

Responding to vulnerability and special needs

16:50 to 18:20
Networking zone 2 (N2)
Kerstin Stenius
Thursday, 24 October
13:20

Focus on prescription drugs I

13:20 to 14:50
Insights zone 3 (I3)
Volker Auwärter

Opioid-related deaths: learning from pharmacology, laboratory-based studies and physical assessments

13:20 to 14:50
Central square 1 (C1)
Sir John Strang

Treatment adherence

13:20 to 14:50
Insights zone 4 (I4)
Marta Torrens Melich

Presentations

  • Plenary session
  • Poster session
  • Big debate
  • Structured session
  • Workshop
  • Oral presentation session
  • Short communication session
  • Poster guided tour

Wednesday, 23 October

13:30
Oral presentation

The advantages and challenges of developing a national earlier warning system - Transforming Bergen Earlier Warning System (BEWS) into Norwegian National Earlier Warning System (NNEWS).

13:30 to 13:45
Insights zone 2 (I2)
Else Kristin Utne Berg
13:45
Oral presentation

New psychoactive substances in Portugal

13:45 to 14:00
Insights zone 2 (I2)
Ludmila Carapinha
14:00
Oral presentation

Recent use of synthetic cannabinoids, synthetic opioids and other psychoactive drug groups among high-risk drug users in Israel.

14:00 to 14:15
Insights zone 2 (I2)
Barak Shapira
14:15
Oral presentation

Use of physiologically based pharmacokinetic modelling of new psychoactive substances

14:15 to 14:30
Insights zone 2 (I2)
Nuno Elvas Silva
14:30
Oral presentation

Combining monitoring data to evaluate responses to NPS: the case of 4-FA in the Netherlands

14:30 to 14:45
Insights zone 2 (I2)
Margriet van Laar
15:10
Short communication

Insights into benzo fury toxicity: 5-(2-aminopropyl)benzofuran and 6-(2-aminopropyl)benzofuran disrupt oxidative, energetic and mitochondrial homeostasis of hepatocytes in vitro

15:10 to 15:20
Networking zone 3 (N3)
Rita Roque Bravo
15:20
Short communication

Tracking NPS in Portugal: the case of MTMP

15:20 to 15:30
Networking zone 3 (N3)
Helena Gaspar
15:30
Short communication

Single binge dosing of 4-Methylethcathinone (4-MEC) induces sturdy and durable cognitive impairment in mice

15:30 to 15:40
Networking zone 3 (N3)
Cristina Sampayo
15:40
Short communication

Abuse potential of new psychoactive substances: N-ethylhexedrone, 4-Methylethcathinone, 4-Fluoromethcathinone and Buphedrone

15:40 to 15:50
Networking zone 3 (N3)
Cristina Sampayo
15:50
Short communication

Studies on the metabolism of synthetic cathinones N-ethylhexedrone and buphedrone using liquid chromatography-mass spectrometry (LC-MS/MS)

15:50 to 16:00
Networking zone 3 (N3)
Joana Carrola
16:00
Short communication

Changa – fist time identification in Portugal

16:00 to 16:10
Networking zone 3 (N3)
Maria João Caldeira
16:10
Short communication

Variations and determinants of novel psychoactive substance use: a mixed methods study to identify the implications for policy and practice

16:10 to 16:20
Networking zone 3 (N3)
Kathryn Higgins
17:00
Oral presentation

Socioeconomic status and parental education in vulnerability for substance use disorders

17:00 to 17:15
Networking zone 2 (N2)
Sabrina Molinaro
17:15
Oral presentation

People with lifelong disability and their experiences of pubs and clubs in Australia

17:15 to 17:30
Networking zone 2 (N2)
Hannah Pitt
17:30
Oral presentation

Hospitalisation of children after prenatal exposure to methamphetamine

17:30 to 17:45
Networking zone 2 (N2)
Svetlana Skurtveit
17:45
Oral presentation

Veterans, substance use and trauma-informed care: analysis of veterans’ treatment needs in a multi-state sample of inmates

17:45 to 18:00
Networking zone 2 (N2)
Michele Pich
18:00
Oral presentation

The association of traumatic experiences, perceived discrimination and affective symptoms with substance use among Russian and Kurdish migrants in Finland: a population-based study

18:00 to 18:15
Networking zone 2 (N2)
Essi Salama

Thursday, 24 October

13:30
Oral presentation

Use of contingency management (positive reinforcement with financial incentives) to encourage abstinence from heroin (PRAISE): a UK cluster randomised trial

13:30 to 13:45
Insights zone 4 (I4)
Nicola MetrebianTimothy Weaver
Oral presentation

The off-prescription use of modafinil: an online survey of perceived risks and benefits

13:30 to 13:45
Insights zone 3 (I3)
Rachel Teodorini
Oral presentation

Understanding opioid drugs and important drug interactions in opioid-related deaths

13:30 to 13:45
Central square 1 (C1)
Graeme Henderson
13:45
Oral presentation

Opioid maintenance treatment (OMT) – not life-long for all women? 10 years follow-up after pregnancy - how many stop OMT and what are the results?

13:45 to 14:00
Insights zone 4 (I4)
Gabrielle Welle-Strand
Oral presentation

Fentanyl overdose: naloxone reversibility and reduced cross tolerance

13:45 to 14:00
Central square 1 (C1)
Rob Hill
Oral presentation

Prospective cohort to assess the impact of removing non-prescription codeine in Australia

13:45 to 14:00
Insights zone 3 (I3)
Jacqui McCoy
14:00
Oral presentation

A look at the dark side of addiction treatment: a profile of those who drop out

14:00 to 14:15
Insights zone 4 (I4)
João Augusto
Oral presentation

Characteristics and problematic opioid use in people prescribed opioids for CNCP over four years: a prospective cohort study

14:00 to 14:15
Insights zone 3 (I3)
Gabrielle Campbell
Oral presentation

Heroin overdose: experimental testing and measurement in the laboratory (preliminary findings)

14:00 to 14:15
Central square 1 (C1)
Basak Tas
14:15
Oral presentation

Methadone serum concentrations and influencing factors: a naturalistic observational study

14:15 to 14:30
Insights zone 4 (I4)
Fatemeh Chalabianloo
Oral presentation

Chronic obstructive pulmonary disease (COPD) among opioid dependent patients in substitution treatment. A diagnostic study

14:15 to 14:30
Central square 1 (C1)
Philip Bruggmann
Oral presentation

A qualitative study of gabapentin use and misuse: perspectives of substance abuse treatment professionals

14:15 to 14:30
Insights zone 3 (I3)
Mance Buttram
14:30
Oral presentation

Is methadone treatment more effective for lower socio-economic status opiate users? Results from a case crossover study in Lazio

14:30 to 14:45
Insights zone 4 (I4)
Antonella Camposeragna
Oral presentation

Analysis of the content of used injecting paraphernalia in the Sydney supervised injecting facility

14:30 to 14:45
Central square 1 (C1)
Elodie Lefrançois